Literature DB >> 34181651

Use of vector control to protect people from sleeping sickness in the focus of Bonon (Côte d'Ivoire).

Dramane Kaba1, Vincent Djohan1, Djakaridja Berté1, Bi Tra Dieudonné Ta1, Richard Selby2, Koffi Alain De Marie Kouadio1, Bamoro Coulibaly1, Gabehonron Traoré1, Jean-Baptiste Rayaisse1,3, Pierre Fauret1,3, Vincent Jamonneau1,3, Kouakou Lingue4, Phillipe Solano3, Steve J Torr2, Fabrice Courtin1,3.   

Abstract

BACKGROUND: Gambian human African trypanosomiasis (gHAT) is a neglected tropical disease caused by Trypanosoma brucei gambiense transmitted by tsetse flies (Glossina). In Côte d'Ivoire, Bonon is the most important focus of gHAT, with 325 cases diagnosed from 2000 to 2015 and efforts against gHAT have relied largely on mass screening and treatment of human cases. We assessed whether the addition of tsetse control by deploying Tiny Targets offers benefit to sole reliance on the screen-and-treat strategy. METHODOLOGY AND PRINCIPAL
FINDINGS: In 2015, we performed a census of the human population of the Bonon focus, followed by an exhaustive entomological survey at 278 sites. After a public sensitization campaign, ~2000 Tiny Targets were deployed across an area of 130 km2 in February of 2016, deployment was repeated annually in the same month of 2017 and 2018. The intervention's impact on tsetse was evaluated using a network of 30 traps which were operated for 48 hours at three-month intervals from March 2016 to December 2018. A second comprehensive entomological survey was performed in December 2018 with traps deployed at 274 of the sites used in 2015. Sub-samples of tsetse were dissected and examined microscopically for presence of trypanosomes. The census recorded 26,697 inhabitants residing in 331 settlements. Prior to the deployment of targets, the mean catch of tsetse from the 30 monitoring traps was 12.75 tsetse/trap (5.047-32.203, 95%CI), i.e. 6.4 tsetse/trap/day. Following the deployment of Tiny Targets, mean catches ranged between 0.06 (0.016-0.260, 95%CI) and 0.55 (0.166-1.794, 95%CI) tsetse/trap, i.e. 0.03-0.28 tsetse/trap/day. During the final extensive survey performed in December 2018, 52 tsetse were caught compared to 1,909 in 2015, with 11.6% (5/43) and 23.1% (101/437) infected with Trypanosoma respectively.
CONCLUSIONS: The annual deployment of Tiny Targets in the gHAT focus of Bonon reduced the density of Glossina palpalis palpalis by >95%. Tiny Targets offer a powerful addition to current strategies towards eliminating gHAT from Côte d'Ivoire.

Entities:  

Year:  2021        PMID: 34181651     DOI: 10.1371/journal.pntd.0009404

Source DB:  PubMed          Journal:  PLoS Negl Trop Dis        ISSN: 1935-2727


  4 in total

1.  Scaling up of tsetse control to eliminate Gambian sleeping sickness in northern Uganda.

Authors:  Andrew Hope; Albert Mugenyi; Johan Esterhuizen; Inaki Tirados; Lucas Cunningham; Gala Garrod; Mike J Lehane; Joshua Longbottom; Tn Clement Mangwiro; Mercy Opiyo; Michelle Stanton; Steve J Torr; Glyn A Vale; Charles Waiswa; Richard Selby
Journal:  PLoS Negl Trop Dis       Date:  2022-06-29

2.  The cost of tsetse control using 'Tiny Targets' in the sleeping sickness endemic forest area of Bonon in Côte d'Ivoire: Implications for comparing costs across different settings.

Authors:  Fabrice Courtin; Dramane Kaba; Jean-Baptiste Rayaisse; Philippe Solano; Steve J Torr; Alexandra P M Shaw
Journal:  PLoS Negl Trop Dis       Date:  2022-01-05

3.  Update of transmission modelling and projections of gambiense human African trypanosomiasis in the Mandoul focus, Chad.

Authors:  Kat S Rock; Ching-I Huang; Ronald E Crump; Paul R Bessell; Paul E Brown; Inaki Tirados; Philippe Solano; Marina Antillon; Albert Picado; Severin Mbainda; Justin Darnas; Emily H Crowley; Steve J Torr; Mallaye Peka
Journal:  Infect Dis Poverty       Date:  2022-01-24       Impact factor: 4.520

4.  The elimination of human African trypanosomiasis: Achievements in relation to WHO road map targets for 2020.

Authors:  Jose R Franco; Giuliano Cecchi; Massimo Paone; Abdoulaye Diarra; Lise Grout; Augustin Kadima Ebeja; Pere P Simarro; Weining Zhao; Daniel Argaw
Journal:  PLoS Negl Trop Dis       Date:  2022-01-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.